Cullgen is a drug discovery company leveraging ubiquitin-mediated, small molecule-induced protein degradation technology. The company's research programs focus on novel treatment for cancer, inflammatory, and autoimmune diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/10/19 | $16,000,000 | Series A |
Highlight Capital | undisclosed |
| 02/25/21 | $50,000,000 | Series B |
3E Bioventures Heights Capital Management Highlight Capital MSA Capital Octagon Capital South China Venture Capital | undisclosed |
